Background 'Not relevant' responses (NRRs) on the Dermatology Life Quality Index (DLQI) may occur in up to 40% of patients with psoriasis. As these responses are scored as the item of the questionnaire having no impact on the patients' lives at all, it is more difficult for these patients to fulfil the DLQI > 10 criterion required by clinical guidelines to become candidates for systemic treatment including biologics. Objectives We propose a new scoring system for the DLQI that corrects for the bias in the NRR option and test its construct validity in a sample of patients with psoriasis. Methods Data from 242 patients (104 of whom marked at least one NRR) from two earlier cross-sectional surveys were reanalysed. For each patient, the DLQI score was calculated in two ways: (i) according to the original scoring and (ii) by applying a new scoring formula (DLQI-R) that adjusts the total score for the number of NRRs. The construct validity of the DLQI-R was tested against the Psoriasis Area and Severity Index (PASI) and EQ-5D-3L. Results The mean DLQI and DLQI-R scores were 9Á99 AE 7Á52 and 11Á0 AE 8Á02, respectively. The DLQI-R allowed eight more patients (3Á3%) to achieve the 'PASI > 10 and DLQI > 10' threshold. The results were robust when limiting the maximum number of NRRs allowed to two or three. Compared with the DLQI, DLQI-R correlated slightly better with PASI (r s = 0Á59 vs. 0Á57) and EQ-5D-3L index scores (r s = À0Á58 vs. À0Á54). Conclusions The DLQI-R seems to be a valid scoring system for avoiding the bias in the NRR option and can help to improve patients' access to biologics.
What are the clinical implications of this work?
• The new scoring can help to improve patients' access to biologics.
The Dermatology Life Quality Index (DLQI) is the most commonly used health-related quality of life (HRQoL) measure used in patients with psoriasis. 1, 2 It is easy to use, it can detect even small differences in patients' health status, it is well embedded in dermatological practice and it is endorsed by professional societies. 3 Along with the Psoriasis Area and Severity Index (PASI), it is a recommended end point for efficacy in clinical trials. 4 Moreover, it is among the core outcomes collected in large registries of patients with psoriasis worldwide. 5 A number of clinical decisions in the management of patients with psoriasis, such as treatment strategy selection, hospital admission and discharge, involve the DLQI. 6 According to current treatment guidelines, moderate-to-severe psoriasis is defined as DLQI > 10 and either PASI > 10 or body surface area (BSA) > 10; this is required for patients to become candidates for systemic therapy including biologics. 7, 8 However, a recent study reported that 'not relevant' responses (NRRs) on the DLQI occurred in up to 40% of patients with psoriasis, especially in the items relating to sport, sexual difficulties and working/studying. 9 As all NRRs are scored as the item having no impact on patients' lives at all, they artificially improve patients' DLQI scores. For these individuals, it might be more difficult to fulfil the DLQI > 10 criterion required by clinical guidelines despite having severe psoriasis. Thus, there is an unmet need to develop a scoring system that takes into account the number of NRRs on the DLQI. In this paper we introduce a new scoring system for the DLQI that corrects for the bias in the NRR option and test its construct validity in a sample of patients with psoriasis.
Patients and methods

Study design and outcome measures
For the purposes of the current study, data from patients with psoriasis from two earlier cross-sectional surveys in Hungary were reanalysed. 10, 11 Patients with psoriasis not treated with biological drugs were included in this analysis. General HRQoL was measured by the EQ-5D-3L and EQ visual analogue scale (EQ-VAS). 12, 13 The EQ-5D-3L is based on five dimensions of HRQoL: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three levels: no problems, some/moderate problems and extreme problems, which results in a total of 3 5 = 243 possible health states. Given the lack of a Hungarian national value set, 14 EQ-5D-3L index scores were calculated according to the U.K. tariff, so values ranged between À0Á594 and 1, where 0 refers to death and 1 to full health. 15 The EQ-VAS records the respondent's self-rated health on a 20-cm vertical line, with end points labelled as 0 (worst imaginable health state) and 100 (best imaginable health state).
Dermatologists provided data on the clinical characteristics of patients and graded disease severity by PASI. PASI scores the severity of disease by the presence of erythema, induration and scaling, and the extension of the lesions in the head, trunk and upper and lower extremities. 16 The total score varies between 0 and 72, where higher scores indicate more severe disease.
Dermatology Life Quality Index scoring methods DLQI was applied to assess skin-specific HRQoL. 1 It consists of 10 questions that can be categorized into the following six subscales: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. In this study, the DLQI total score was calculated in three ways for each patient. Firstly, we used the original scoring guidelines 1 according to which the 10 items of the questionnaire are each rated on a four-point scale ('not at all' or 'not relevant' = 0, 'a little' = 1, 'a lot' = 2 and 'very much' = 3), yielding a total score of 0-30, where a higher score represents a greater impairment of HRQoL. The original scoring formula of the DLQI is summarized in the following equation:
where i indicates the items of the questionnaire, for example dlqi 1 is the score in first item of the questionnaire. Secondly, a new scoring formula was applied that eliminates the 'not relevant' items of the DLQI, and thereby adjusts the total score to the relevant items. This scoring (hereafter abbreviated as DLQI-R, where R corresponds to the term 'relevant') is described by the following equation:
For example, let us suppose that patients with a DLQI total score of nine ticked two NRRs, thus their DLQI-R score would be 9 9 [10 / (10 -2)] = 11Á3. A simple summary of the DLQI-R scoring formula according to the number of NRRs is presented in Table 1 . Note that only eight out of the 10 questions have an NRR option.
Thirdly, as a sensitivity analysis of the DLQI-R scoring, we applied an alternative scoring calculation (hereafter abbreviated as DLQI-SF, where SF refers to symptoms and feelings) that took into consideration only the first two items of the questionnaire (symptoms and feelings subscale) according to the equation below:
where dlqi 1 and dlqi 2 refer to the scores in the first ('over the last week, how itchy, sore, painful, or stinging has your skin been?') and second items ('over the last week, how embarrassed or self-conscious have you been because of your skin?') of the original DLQI questionnaire. As an example, let us suppose that if patients marked 'very much' in the first item and 'a little' in the second, their score would be DLQI-SF = (3 + 1) 9 5 = 20. There are two arguments underpinning the feasibility of this alternative scoring formula. Firstly, in a recent study, Stull et al. 17 performed structural equation modelling and showed that in patients with psoriasis, the symptoms of psoriasis first affect the symptoms and feelings subscale, which then has an impact on the remaining five subscales. Secondly, the first two questions of the DLQI are those that offer no NRR options.
Data analysis
Analyses were carried out separately for the total sample, and then for the subsample of those patients who provided at least one NRR on the DLQI. Descriptive statistics were computed for demographic and clinical variables. Mean DLQI total scores and the number of patients who achieved the 'PASI > 10 and DLQI > 10' threshold were calculated by all three DLQI scoring methods presented above. DLQI, DLQI-R and DLQI-SF scores were classified based on the bands proposed by Hongbo et al. 18 The bands describe the overall impact of skin disease on HRQoL: 0-1 = no effect, 2-5 = small effect, 6-10 = moderate effect, 11-20 = very large effect and 21-30 = extremely large effect. Two different approaches were used for sensitivity analysis. Firstly, we varied the number of NRRs allowed in the formula of DLQI-R: (i) a maximum of three NRRs and (ii) a maximum of two NRRs. Secondly, the effect of an alternative scoring (DLQI-SF) on scores was examined. Both the DLQI-R and DLQI-SF scores were plotted against the original DLQI scores of the patients. To test construct validity, we analysed the correlation of DLQI, DLQI-R and DLQI-SF scores with PASI, EQ-5D-3L index and EQ-VAS scores. For absolute values of Spearman's correlation coefficients, 0-0Á19 was considered as very weak, 0Á20-0Á39 as weak, 0Á40-0Á59 as moderate, 0Á60-0Á79 as strong and 0Á80-1 as a very strong correlation. 19 All statistical analyses were performed using SPSS 22Á0 (IBM, Armonk, NY, U.S.A.).
Results
Overall, 242 patients met the inclusion criteria, 104 (43Á0%) of whom had at least one NRR on the DLQI. There were 50 patients (20Á7%) with one NRR, 30 (12Á4%) with two NRRs, 16 (6Á6%) with three NRRs, five (2Á1%) with four NRRs, one (0Á4%) with five NRRs and two (0Á8%) with six NRRs. Table 2 provides details about the clinical characteristics of the patients. In the total sample, the mean DLQI, DLQI-R and DLQI-SF scores were 9Á99 AE 7Á52, 10Á98 AE 8Á02 and 14Á75 AE 9Á24 points, respectively (Table S1 ; see Supporting Information). The corresponding scores in the subsample of patients with NRRs were 9Á49 AE 5Á83, 11Á79 AE 7Á16 and 16Á20 AE 8Á80. The order of mean values (DLQI < DLQI-R < DLQI-SF) was consistent in the subgroups of patients based on sex, age Number of NRRs DLQI-R score 1 DLQI 9 10/9 = DLQI 9 1Á11 2 DLQI 9 10/8 = DLQI 9 1Á25 3 DLQI 9 10/7 = DLQI 9 1Á43 4 DLQI 9 10/6 = DLQI 9 1Á67 5 DLQI 9 10/5 = DLQI 9 2 6 DLQI 9 10/4 = DLQI 9 2Á5 7 DLQI 9 10/3 = DLQI 9 3Á33 8 DLQI 9 10/2 = DLQI 9 5 DLQI-R, Dermatology Life Quality Index adjusted for NRRs. The maximum number of NRRs is eight, as the first two items of the DLQI have no NRR options. groups and clinical forms. For most patients, the DLQI-R only slightly raised the score compared with the original DLQI, whereas the DLQI-SF led to a large increase in scores (Fig. 1) . The proportions of DLQI, DLQI-R and DLQI-SF scores according to the bands of Hongbo et al. are presented in Figure 2 . The DLQI-R scoring allowed eight more patients (3Á3% of the total sample and 7Á7% of the subsample of patients with NRRs) to achieve the 'PASI > 10 and DLQI > 10' threshold (Table S1 ). The results were robust when limiting the maximum number of NRRs to two or three. In contrast, the DLQI-SF scoring enabled a total of 17 patients (7Á0% of the total sample) to reach the threshold of 'PASI > 10 and DLQI > 10'. All three DLQI scoring methods produced significant moderate correlations with PASI and EQ-5D-3L index but weak correlations with EQ-VAS ( Table 3 ). The DLQI-R correlated slightly better with PASI, EQ-5D-3L index and EQ-VAS scores than either the original DLQI or DLQI-SF in the total sample, as well as in the subsample of patients with NRRs (P < 0Á01). It is notable that DLQI-R produced better correlations with DLQI than DLQI-SF.
Discussion
This study aimed to propose a new simple scoring formula for the DLQI questionnaire in psoriasis that eliminates the items marked as 'not relevant' while increasing the weight of the relevant items in the total score. The DLQI-R scoring offers three major advantages: (i) no amendments are needed to the original scoresheet of the DLQI; (ii) it changes the DLQI score only in a subgroup of patients who are affected by the NRR option without making the situation of others worse; and (iii) it may be easily applied to previously collected DLQI data to facilitate comparison across studies. In this discussion we provide a comprehensive summary of the implications of the proposed DLQI-R scoring, such as psychometric testing, the interpretability of scores, recommendations for treatment guidelines, applicability in daily clinical practice and the possibility to extrapolate the scoring to conditions other than psoriasis.
The psychometric performance of the DLQI has been widely investigated. The preponderance of evidence supports its validity, reliability and responsiveness in psoriasis. 2, 20 However, there exists a growing body of literature questioning key aspects of its validity including the lack of unidimensionality; 21 28 and discrepancies identified between DLQI scores and health utility values. 29, 30 As a part of this proposal, we evaluated the construct validity of DLQI-R. In terms of correlations with other core outcome measures, such as PASI, EQ-5D-3L and EQ-VAS, the DLQI-R performed better than the original DLQI. A next step to confirm the validity of the DLQI-R would be to examine the veracity of NRRs (i.e. whether patients can differentiate between the terms 'not relevant' and 'not at all'). Given that the DLQI-R is based entirely on the original DLQI scoresheet, its reliability is anticipated to remain unchanged when applying the DLQI-R scoring formula. Regarding the assessment of responsiveness, the difference between baseline and post-treatment DLQI scores is influenced not only by the change in health status over time but also by whether 'not relevant' items become relevant for certain patients. Aside from the rare times when the total DLQI score decreases along with an increase in the number of NRRs, the responsiveness properties of the DLQI-R are expected to improve compared with the DLQI. In future studies, the psychometric properties of the DLQI-R should be confirmed using previously collected longitudinal data, preferably from a randomized controlled trial.
We have compared the performance of the DLQI-R with that of a possible alterative scoring, DLQI-SF, which takes into account only the symptoms and feelings subscale of the questionnaire. The most salient difference between the results of the DLQI-R and DLQI-SF is that the DLQI-SF scores are much higher than the original DLQI scores and allow for considerably more patients to reach the 'PASI > 10 and DLQI > 10' threshold. The DLQI-SF demonstrates a clear tendency to overestimate HRQoL impairment of patients; for example, if they report a little problem in the first two questions of the DLQI, their original DLQI score would be 2, whereas their DLQI-SF score would be as high as 10 points, which almost fulfils the diagnostic criteria for moderate-to-severe psoriasis. Moreover, as opposed to the DLQI-R, which only slightly changes the distribution of the original scores, the DLQI-SF scores show limited variability; they can take on only seven values (i.e. 0, 5, 10, 15, 20, 25, 30) (Fig. 1) .
A great advantage of the DLQI is that easily interpretable meanings can be assigned to scores. Finlay put forward the concept of the 'rule of tens' (BSA > 10, PASI > 10 or DLQI > 10) to define current severe psoriasis, 33 and Hongbo et al. proposed a banding system 18 to aid the interpretation of DLQI scores. [34] [35] [36] [37] Various values for DLQI minimal clinically important difference (MCID) have been reported, ranging between 2Á3 and 5 points. Basra et al. set the MCID in psoriasis at 4 points. 2, 20 By adjusting DLQI scores for the NRRs it is not clear whether the original MCID and score bandings remained identical. The potential effect of DLQI-R scoring on these values depends on the number of patients with NRRs in a population that might be subject to large variability. Validation studies of the DLQI that estimated the MCID provided no data on NRRs in patients with psoriasis. [34] [35] [36] Very few authors reported on the total number of NRRs in patients with psoriasis, and only one study indicated the rate of patients with more than one NRR. 8 According to these data, on average 5-39% of people across populations of patients with psoriasis marked at least one NRR. 9, 21, 31, 32, [38] [39] [40] As not all patients are affected by NRRs, it may be tempting to interpret scores based on DLQI-R using the same MCID and score bandings. Nevertheless, a formal study with anchoring questions is warranted to test the potential need to modify the DLQI banding when using DLQI-R instead of DLQI. According to the European S3-guidelines on the systemic treatment of psoriasis vulgaris, moderate-to-severe psoriasis is defined as DLQI > 10 along with either PASI > 10 or BSA > 10. This is required for patients to become candidates for systemic therapy including biologics. 7, 8 In many European countries such as the U.K., Sweden, Denmark, Italy, Spain, Hungary, Poland, Romania and Croatia, national treatment and reimbursement guidelines have adopted this definition. [41] [42] [43] [44] [45] [46] The literature suggests that stricter PASI and DLQI criteria in national guidelines may be responsible for the limited access to biologics. 42 As the DLQI-R scoring is specifically proposed to be used in treatment decisions, professional societies and authors of guidelines at both European and national levels might consider allowing or disallowing the DLQI-R formula under their own authority. Another important point for consideration when developing a recommendation is the maximum number of NRRs allowed under the DLQI-R scoring when it comes to treatment decisions. As most studies observed the vast majority of NRRs to be present in three items of the DLQI (sports, sexual difficulties and working/studying), 9, 21, 31, 32, [38] [39] [40] a maximum of three NRRs is suggested to be allowed, until further psychometric evidence is available. This is confirmed by the results of our sensitivity analysis: the number of patients who achieved the 'PASI > 10 and DLQI > 10' threshold remained the same when the number of NRRs in the formula was maximized at three. The popularity of the DLQI in clinical practice is grounded in its simplicity and brevity (the average completion time is 
The data are Spearman's rank order correlations, with P < 0Á01 for all correlation coefficients. DLQI, original scoring; DLQI-R, DLQI adjusted for 'not relevant' responses (NRRs); DLQI-SF, only the symptoms and feelings subscale of the DLQI is included; PASI, Psoriasis Area and Severity Index; VAS, visual analogue scale.
about 2 min) 47 and the large amount of knowledge accumulated with its use over the past two decades. Putting the DLQI-R into practice would require clinicians to look up or memorize the multipliers presented in Table 1 , which could be troublesome. Nevertheless, we believe that in certain circumstances, for example, when treatment decisions are made, the benefits are likely to compensate physicians for the extra time that it takes to look up the formulae and calculate the DLQI-R scores. It may be a concern with DLQI-R that overinterpretation of scores could move away from the simple concepts on which the widespread use and practicality of the DLQI is based. With practitioners being aware of this, the use of the DLQI-R might be recommended only in defined situations in the first instance. The DLQI is used in many clinical circumstances, including observational studies, clinical trials, decisions on therapy and/or hospitalization and treatment monitoring. Of these, the DLQI-R would be particularly useful in situations where clinical decisions are involved, for example the decision on the introduction of systemic treatment including biologics.
It is an open question whether expanding the use of the DLQI-R to some other set of circumstances would be of real clinical benefit.
Given that the DLQI is not a psoriasis-specific but a skinspecific HRQoL measure, the DLQI-R scoring approach theoretically may be used in any dermatological diagnosis. However, again, demonstrating the validity of the DLQI-R is necessary in these conditions too. As the primary aim of the DLQI-R is to ensure that patients with psoriasis do not miss out on being eligible for biologics based on DLQI criteria set out by clinical guidelines, it may be extrapolated to other conditions in which treatment guidelines specify DLQI thresholds similar to those for psoriasis. For example, oral alitretinoin is recommended for adult patients with severe chronic hand eczema having a DLQI score of ≥ 15 in the U.K. 48 Testing the DLQI-R scoring in hidradenitis suppurativa and atopic dermatitis, where biologics are currently in their early era, would also be very useful. In these conditions ongoing guideline development can also benefit from such efforts.
In conclusion, the DLQI-R scoring formula seems to be a valid approach for avoiding the possible bias in the NRR option of the DLQI. The novel scoring primarily strives to provide fair access to systemic treatments for patients with psoriasis who cannot comply with the DLQI criteria in treatment guidelines because certain items of the questionnaire are simply not relevant to them. However, given the extensive use of the DLQI, the implications of the DLQI-R scoring may reach far wider than psoriasis care. We hope that this proposal will result in future research into the applicability of the DLQI-R and we invite further discussion of this issue among psoriasis expert groups and professional societies.
